ArriVent BioPharma, Inc. Common Stock (AVBP) Stock Price

AVBPStock
$31.35+46.48%52W
Market Cap$1.55B
P/E
PEG Ratio
Div yield
Beta1.41

AVBP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)15.70%
Price vs S&P 500 (4W)-7.05%
VGM Score64.13

AVBP Earnings Surprise History

Q2 25-0.90est. -0.71
Q3 25-0.83est. -0.78
Q4 25-0.78est. -0.85
Q1 26-0.96est. -0.89
Q2 26-1.05est. -0.98

AVBP Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.32
4.32
4.32
4.33

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
AVBPArriVent BioPharma, Inc. Common Stock
B$31.35
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About ArriVent BioPharma, Inc. Common Stock

ArriVent BioPharma is a clinical-stage biopharmaceutical company developing differentiated cancer therapeutics with an initial focus on solid tumors. The company's lead candidate, furmonertinib, is in clinical development, supported by a pipeline that includes next-generation antibody-drug conjugates designed to address unmet oncology needs.